Highlights
- •New KDIGO Guidelines recommend straight blood pressure control in renal disease.
- •Available evidence shows a J Curve effect of blood pressure control on morbimortality in kidney disease patients.
- •Intensive blood pressure control should be avoided in most chronic kidney disease patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Kidney disease: improving global outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease.Kidney Int. 2021; 99: S1-S87
- ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines.J Am Coll Cardiol. 2017; 71 (2018 May 15): e127-e248https://doi.org/10.1016/j.jacc.2017.11.006
- A randomized trial of intensive versus standard blood-pressure control.N Engl J Med. 2015; 373: 2103-2116
Williams B, Mancia G, Spiering W, et al.; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041.
- Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensinconverting enzyme inhibition: a patient-level meta-analysis.Ann Intern Med. 2003; 139: 244-252
- Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier.Ann Intern Med. 2011; 154: 541-548
- Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population.J Am Coll Cardiol. 2014; 64: 588-597
- Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension.Lancet. 1979; 1: 861-865
- The j-point phenomenon in aggressive therapy of hypertension: new insights.Curr Atheroscler Rep. 2012; 14: 124-129
- Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.Eur Heart J. 2019; 40: 2032-2043
- Antihypertensive treatment and renal protection: is there a J-curve relationship?.J Clin Hypertens (Greenwich). 2018; 20: 1560-1574
- Does a blood pressure J curve exist for patients with chronic kidney disease?.J Clin Hypertens (Greenwich). 2017; 19: 764-770
- SPRINT Research Group. Effects of intensive BP control in CKD.J Am Soc Nephrol. 2017; 28: 2812-2823
- Target blood pressure for treatment: should current recommendations be changed?.Hypertension. 2016; 68 (Aug): 263-265
- Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of >160 mmHg and a Lower Framingham risk score: a cautionary note from SPRINT.in: European Society of Cardiology 2017 Congress. 2017 (August 28Barcelona, Spain. Abstract 3828)
- Influence of baseline systolic blood pressure on the relationship between intensive blood pressure control and cardiovascular outcomes in the Systolic Blood Pressure Intervention Trial (SPRINT).Clin Res Cardiol. 2019; 108: 273-281
- Evaluation of optimal diastolic blood pressure range among adults with treated systolic blood pressure less than 130 mm Hg.JAMA Netw Open. 2021; 4 (Feb 1PMID: 33595663; PMCID: PMC7890449)e2037554https://doi.org/10.1001/jamanetworkopen.2020.37554
Article info
Publication history
Published online: September 29, 2021
Accepted:
September 17,
2021
Received in revised form:
August 20,
2021
Received:
June 28,
2021
Identification
Copyright
© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
